Recent Updates
Recently added Catalysts

Milrinone

Phase 2

Valvular Stenosis | Small molecule | Cardiovascular |Stoke Therapeutics, Inc.|Last Updated: Oct 25, 2013

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment124
FDA Designations
No designations recorded
Clinical trial landscape

Milrinone · 1 trial · 4 indications

Phase 2 1
NCT00819377Milrinone Inhaled in Cardiac SurgeryValvular Stenosis
COMPLETED124 Analytics
PHASE2COMPLETED
Milrinone Inhaled in Cardiac Surgery
Valvular StenosisUnlock trial analytics
Study Endpoints
Primary Endpoints
To demonstrate that inhaled milrinone administered before CPB is superior to placebo in reducing the severity of difficult separation from bypass
End of CPB
Secondary Endpoints
Reduction in morbidity and mortality post-op
At discharge, 3 months, 6 months and 1 year by telephone
Reduction in pulmonary artery pressure
Same day before and after CPB
Right ventricular function measured using transthoracic echocardiography (TTE) and TEE
Same day before and after the CPB
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Normal salinePLACEBO_COMPARATORNormal saline by inhalation over 15 min
MilrinoneACTIVE_COMPARATORInhaled milrinone 5 mg(as for the injectable solution)
Interventions
NameTypeDescription
MilrinoneDRUGinhaled milrinone 5 mg (as for the injectable solution)
Normal salineDRUG5 ml normal saline by inhalation over 15 min
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to 90 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Adult patients scheduled for elective valvular or complex (2 or more valves or * valve and revascularization) cardiac surgery under CPB with preoperative PHT defined as mean pulmonary artery pressure (MPAP) over 30 mmHg or * systolic pulmonary artery pressure (SPAP) over 40 mm...

Countries:Canada
Unlock Eligibility Criteria